Sam Sulek on peptides: hype vs. what studies actually show

What did @gymclipsforyou04 actually say?

The creator, riffing on Sam Sulek's apparent comments about peptides, made a fairly specific argument: peptide products are fad-driven, peptide companies are often barely companies at all, and the whole space sits in what they called an "unregulated gray area." They also threw creatine and ashwagandha into the mix as examples of products that get hyped because they're sellable on social media, not because they're necessarily transformative. The overall tone was skeptical but not alarmist, and notably they did not make any bold therapeutic claims about specific peptides.

The creator deserves some credit here. Rather than pumping a peptide stack, they were essentially telling their audience to be cautious. That's not the usual influencer playbook. But their framing mixed up a few things worth untangling, including what "unregulated" actually means in this context and whether lumping peptides in with ashwagandha as a social media fad is really accurate.

Does the science back this up?

The "gray area" framing is largely correct, but it needs more precision. The regulatory picture for peptides in the U.S. is genuinely complicated, and calling it a gray area is not an exaggeration.

The FDA has removed several peptides, including BPC-157 and TB-500, from the list of bulk drug substances that compounding pharmacies can use under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. As of 2023, BPC-157 in particular is not legal for compounding by most pharmacies in the U.S., though enforcement is inconsistent. This is documented in FDA guidance documents, not fringe opinion.

On the quality control side, a 2023 analysis published in JAMA Internal Medicine by Cohen et al. examined peptide and research chemical products sold online and found significant labeling inaccuracies and contamination risks. That's not a theoretical concern. It's a documented problem with exactly the kind of vendors the creator was gesturing at when they said "sometimes companies is kind of a stretch."

Where the science gets murkier is in clinical evidence for most of these compounds. BPC-157 has shown interesting results in rodent models for gut healing and tendon repair, but there are no large-scale randomized controlled trials in humans as of 2024. The preclinical data is real; the clinical translation is unproven.

What did they get wrong (or right)?

They got the regulatory skepticism right. The peptide market in the U.S. is genuinely poorly policed, and buyers often have no reliable way to verify purity or dosing accuracy. On that point, the creator is on solid ground.

What they got slightly wrong, or at least oversimplified, is bundling peptides with ashwagandha and creatine as equivalent social media fads. Creatine and ashwagandha actually have substantial human clinical trial data. Creatine monohydrate is one of the most studied ergogenic aids in sports science, with meta-analyses like Lanhers et al. (2017, European Journal of Sport Science) confirming its efficacy for strength and power output. Ashwagandha has legitimate randomized controlled trial support for stress and cortisol modulation, including Chandrasekhar et al. (2012, Indian Journal of Psychological Medicine).

Peptides, by contrast, are mostly at the animal model or small pilot study stage for the use cases fitness influencers discuss. So the fad label might actually undersell how unproven peptides are relative to those other supplements, not just how hyped they are. The creator implied they're all equivalent fads. The evidence gap between them is real and worth naming.

What should you actually know?

If you're considering peptide use for recovery or performance, the regulatory and quality risk is the most immediate concern. You are often buying from vendors with no pharmaceutical-grade manufacturing standards, no third-party testing, and no legal accountability in the traditional supplement sense.

The FDA's removal of BPC-157 and several other peptides from approved compounding substance lists means that legitimate telehealth or compounding pharmacy channels have fewer legal options than they did even two years ago. This is an active regulatory situation, not a stable one.

On the science side, the honest answer is that the most hyped fitness peptides lack the human clinical evidence to justify strong claims about healing or recovery. That does not mean the preclinical data is meaningless, it means the translation from rat studies to human outcomes has not been demonstrated at the level that would satisfy a reasonable standard of evidence. Anyone telling you otherwise is ahead of the data.

The creator's instinct to tell people to be cautious is sound. The mechanisms behind that caution are more specific than "it's a fad," and understanding those specifics matters before making a purchase decision.